Genmab Builds Oncology Portfolio With $1.8B Deal
Danish biotechnology company Genmab announced Wednesday that it would acquire private cancer drugmaker ProfoundBio for $1.8 billion in cash, a move set to beef up Genmab's oncology portfolio and position the...To view the full article, register now.
Already a subscriber? Click here to view full article